Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery Sy… (NCT06948760) | Clinical Trial Compass
CompletedNot Applicable
Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D
United States11 participantsStarted 2025-07-23
Plain-language summary
A randomized controlled trial of Control-IQ, assessing glycemic control (time-in-range 70-180 mg/dL) for Lyumjev insulin (in which the insulin settings have been determined using an experimental conversion factor) as compared to Humalog or Novolog (using optimized settings)
Who can participate
Age range12 Years – 22 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥12.0 and ≤22 years old at time of consent
✓. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year
✓. HbA1c \>6.5 - 12%
✓. Currently using insulin for at least six months
✓. Currently using the Tandem t:slim insulin pump with Control-IQ Technology® for at least two months
✓. Using insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections
✓. Access to internet and willingness to upload data during the study as needed, including data generated prior to the start of the study
✓. For females, not currently known to be pregnant or breastfeeding
Exclusion criteria
✕. History of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment
✕. Severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months prior to enrollment
✕. Current HbA1c \<6.5 or \>12
✕. Pregnancy or intent to become pregnant during the trial
✕. Currently being treated for a seizure disorder